Merck & Co. Inc. diskutieren
Merck & Co. Inc.
WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Aktie / Pharmazeutika / Large Cap /
128,00 €
0,19 %
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating. They now have a $135.00 price target on the stock, up previously from $125.00.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Barclays PLC from $130.00 to $135.00. They now have an "overweight" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Barclays PLC from $135.00 to $145.00. They now have an "overweight" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at UBS Group AG from $135.00 to $148.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Truist Financial Co. from $122.00 to $139.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at Societe Generale from a "hold" rating to a "sell" rating. They now have a $104.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $142.00 price target on the stock, up previously from $139.00.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Berenberg Bank from $140.00 to $143.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Truist Financial Co. from $142.00 to $143.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at Argus to a "strong-buy" rating.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Neueste Beiträge
Canaccord_Genuity_Gr in Ultragenyx Pharmaceutical Inc. diskutieren